Issue 65 March - April 2015

Generic cancer drugs that we can trust

Generics markets are gearing up for the expiry of patents on some of the first targeted cancer drugs. ItÂ’s good news for greater access, but patients want reassurance that switching to generics wonÂ’t put them at risk.

Read More ...
Issue 65 March - April 2015

Side effects of targeted treatments: clinicians' perceptions, patients' realities

The side effects of targeted drugs are poorly documented, and their impact on patients frequently seriously underestimated and undertreated. Efforts to address these issues could improve survival as well as quality of life.

Read More ...
Issue 65 March - April 2015

Walking the line between quick access and evidence

How do you decide which new cancer drugs to approve, when statistical certainty takes too long to wait for and essential evidence on quality of life is hard to measure? The head of the cancer section at the European Medicines Agency is keen to explain his approach.

Read More ...
Issue 65 March - April 2015

Better outcomes data lead to better outcomes

We need to greatly improve our ability to monitor the impact of treatments on outcomes.

Read More ...
Issue 64 January - February 2015

Caring for one of our own

When youÂ’re caring for a patient and friend, who was recently your colleague, working out boundaries and negotiating the particular privileges and pressures of caring for them can be hard. The problem was explored in a Schwartz Center Round* at the Massachusetts General Hospital.

Read More ...